4fs3

Publication Abstract from PubMed

The mechanism of action of AFN-1252, a selective inhibitor of S. aureus enoyl-ACP reductase (FabI) which is involved in fatty acid biosynthesis, was confirmed using biochemistry, macromolecular synthesis, genetics and co-crystallization of a AFN-1252:FabI complex. AFN-1252 demonstrated low propensity for spontaneous resistance development; time-dependent reduction in viability of both MSSA and MRSA, achieving a >/=2 log(10) reduction in S. aureus counts over 24 hours; and was extremely potent against clinical isolates of S. aureus (MIC(90) 0.015 mug/mL) and coagulase-negative staphylococci (MIC(90) 0.12 mug/mL) regardless of their drug-resistance, hospital- or community-associated origin or other clinical sub-group. AFN-1252 was orally available in mouse pharmacokinetic studies and a single oral dose of 1 mg/kg AFN-1252 was efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith. An ED(50) of 0.15 mg/kg indicated that AFN-1252 was 12- to 24 times more potent than linezolid in the model. These studies, demonstrating a selective mode of action, potent in vitro activity and in vivo efficacy support the continued investigation of AFN-1252 as a targeted therapeutic for staphylococcal infections.

AFN-1252 - Mode of action, in vitro activity and in vivo efficacy of a selective anti-staphylococcal FabI inhibitor.,Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW Antimicrob Agents Chemother. 2012 Sep 4. PMID:22948878^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.